@NatRevClinOncol Reference 177 is wrong. Should be Virtakoivu et al. Clin Can Res 2021: https://t.co/d1DLLMi5QG
Phase 1/2 Study: Macrophage targeted immunotherapy. https://t.co/XKAWl4HdnR https://t.co/vld1ZgnK8C
Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial https://t.co/pQCF4Z6cj4
Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial https://t.co/3pxSb0sQMC
RT @CCR_AACR: Adaptive immune activation can be achieved in advanced cancer by modulating endo-lysosomal acidification and antigen degradat…
RT @CCR_AACR: Adaptive immune activation can be achieved in advanced cancer by modulating endo-lysosomal acidification and antigen degradat…
Adaptive immune activation can be achieved in advanced cancer by modulating endo-lysosomal acidification and antigen degradation in #macrophages. Targeting scavenger receptors may provide an immunotherapeutic strategy. @maijahollmen https://t.co/6tPDcF6WeK
Inhibition of a macrophage scavenger receptor Clever-1 has shown benefit in inducing CD8+ T-cell-mediated antitumor responses in mouse models of cancer, which supports the clinical development of Clever-1-targeting antibodies for cancer treatment. https://
Systemic blockade of Clever-1 elicits lymphocyte activation alongside checkpoint molecule downregulation in patients with solid tumors: Results from a phase I/II clinical trial - https://t.co/IUpZ2aBs5S
Systemic blockade of Clever-1 elicits lymphocyte activation alongside checkpoint molecule downregulation in patients with solid tumors: Results from a phase I/II clinical trial #HelsinkiHealth #tutkimus #tiede https://t.co/pvpXMBILsr
Systemic blockade of Clever-1 elicits lymphocyte activation alongside checkpoint molecule downregulation in patients with solid tumors: Results from a phase I/II clinical trial | Clinical Cancer Research https://t.co/nR3q5laGae
A novel antibody drug reactivates the immune defense in patients with advanced-stage cancer by altering the function of the bodys phagocytes and facilitating extensive activation of th... https://t.co/xYWZenpv6m #health #science #tech
https://t.co/HUKURYzWR3 A novel antibody drug reactivates the immune defense in patients with advanced-stage cancer by altering the function of the body’s phagocytes and facilitating extensive activation of the immune system. The treatment may benefit pati
Systemic blockade of Clever-1 elicits lymphocyte activation alongside checkpoint molecule downregulation in patients with solid tumors: Results from a phase I/II clinical trial - https://t.co/IUpZ2aBs5S
Very interesting study from @maijahollmen lab and collaborators indicating Bexmarilimab may benefit patients whom their current treatment are ineffective. The antibody binds the Clever 1 on macrophages and alters its function. https://t.co/QJLloVSdA1
Systemic blockade of Clever-1 elicits lymphocyte activation alongside checkpoint molecule downregulation in patients with solid tumors: Results from a phase I/II clinical trial https://t.co/dToGnK9KFT
RT @maijahollmen: Our study is out showing the first-in-man results with #Clevegen accross multiple solid tumors. Promising anti-tumor acti…
RT @maijahollmen: Our study is out showing the first-in-man results with #Clevegen accross multiple solid tumors. Promising anti-tumor acti…
RT @maijahollmen: Our study is out showing the first-in-man results with #Clevegen accross multiple solid tumors. Promising anti-tumor acti…
RT @maijahollmen: Our study is out showing the first-in-man results with #Clevegen accross multiple solid tumors. Promising anti-tumor acti…
RT @maijahollmen: Our study is out showing the first-in-man results with #Clevegen accross multiple solid tumors. Promising anti-tumor acti…
Our study is out showing the first-in-man results with #Clevegen accross multiple solid tumors. Promising anti-tumor activity for a macrophage targeted immunotherapy. We also describe interesting mode of action. https://t.co/ztqB8BENND